KAT2B and renal carcinoma: For example, in renal cancer organoid models, epigenetic silencing of KAT2B through promoter hypermethylation was shown to drive metabolic reprogramming and tumor progression; restoration of KAT2B or inhibition of its downstream target of FASN-suppressed organoid growth [107].